OCT 26, 2020 1:04 PM PDT

Investigating the Receptor Protein FPR1 in Brain Cancer

WRITTEN BY: Jasper Cantrell

Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – usually involved in transmitting signals into the cell – and are key signal gateways. Therefore, blocking a single receptor could stop whole signal pathways in the cell and maybe even stop cancer in its tracks.

Researchers have identified a new receptor, formylpeptide receptor 1 (FPR1), that might be a good target for anti-cancer drugs. This receptor is part of a family of receptors involved in chemotaxis (a part of how cells move) for immune cells called leukocytes. Recent studies have found that FPR1, in particular, plays a pro-cancer role in many tumor types.

In a new study, a team out of the University of Bradford in the United Kingdom wanted to investigate if FPR1 played a role in colorectal cancer. Other studies have already linked it to brain, colon, and breast cancers, but there wasn’t any evidence of it playing a part in colorectal cancer. There is even evidence that it has a role in resistance and recurrence.

The team would analyze FPR1 expression in colorectal cancer in vitro and in vivo with several other cancer types used as controls to investigate their hypothesis. They would also test how a robust FPR1 inhibitor, developed by the same team in a previous study, would affect cancer cells in the same models.

They first investigated FPR1 levels in a variety of cancer cell lines in vitro. They found that colorectal cancer indeed had FPR1 levels similar to other studied cancers. They also saw an interesting correlation between FPR1 levels and ANXA (an activator of FPR1) levels in hypoxic/necrotic conditions in the brain cancer cell line both in vitro and in vivo.

After the interesting finding with the brain cancer cell line, the team decided to pivot to investigating FPR1’s role there. They tested the FPR1 inhibitor they had developed in a previous study, ICT12035 could prevent the FPR1 dependent cancer growth. They induced FPR1 using an activator molecule, fMLF, which increased cell invasion in the brain cancer cell line. The inhibitor's application effectively prevented this increase in cell invasion and could even suppress cancer cell growth in mouse models.

This study showed that FPR1 was indeed expressed in colorectal cancer as in other cancer types. After an interesting find in a brain cancer cell line, the team shifted their testing. Using the brain cancer cell line, they saw that the FPR1 inhibitor ICT12035 could suppress cancer growth both in vitro and in a mouse model. They also saw that hypoxic conditions, often found in tumors, have higher levels of FPR1, inferring the receptor may play a role in tumor formation or maintenance.

The study concludes, “Further investigation of ICT12035, or other FPR1 antagonists, can open opportunities for more efficient treatment for cancers, including glioma, in due course.”

Sources: Nature Scientific Reports, khanacademymedicine

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUN 10, 2021
Clinical & Molecular DX
Algorithm Flags High Risk of Pancreatic Cancer
JUN 10, 2021
Algorithm Flags High Risk of Pancreatic Cancer
In 2021, over 60,000 individuals in the U.S. alone will be diagnosed with pancreatic cancer. Researchers are turning to ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
JUN 21, 2021
Cancer
Analyzing breast implant topography and associated immune responses
JUN 21, 2021
Analyzing breast implant topography and associated immune responses
In an effort to understand how breast implants influence the immune system, researchers from MIT have led an analysis to ...
JUL 23, 2021
Cancer
New Drug Eradicates Breast Cancer Tumors in Days
JUL 23, 2021
New Drug Eradicates Breast Cancer Tumors in Days
A new drug can kill between 95 and 100% of cancer cells in mice with human estrogen-receptor-positive breast cancer. The ...
JUL 26, 2021
Genetics & Genomics
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
JUL 26, 2021
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
Many types of cells have to be replenished continuously throughout our lives, and the genome in the nucleus of those cel ...
AUG 12, 2021
Cancer
Promising Drug Target Identified for Deadly Ovarian Cancer
AUG 12, 2021
Promising Drug Target Identified for Deadly Ovarian Cancer
Scientists at the University of Alabama at Birmingham have identified a gene called DOT1L for its role in progressing th ...
Loading Comments...